ID16781A - Formulasi-formulasi farmasi - Google Patents

Formulasi-formulasi farmasi

Info

Publication number
ID16781A
ID16781A IDP970927A ID970927A ID16781A ID 16781 A ID16781 A ID 16781A ID P970927 A IDP970927 A ID P970927A ID 970927 A ID970927 A ID 970927A ID 16781 A ID16781 A ID 16781A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
IDP970927A
Other languages
English (en)
Inventor
Arup K Roy
Lioyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID16781A publication Critical patent/ID16781A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDP970927A 1996-03-22 1997-03-21 Formulasi-formulasi farmasi ID16781A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ID16781A true ID16781A (id) 1997-11-13

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970927A ID16781A (id) 1996-03-22 1997-03-21 Formulasi-formulasi farmasi

Country Status (12)

Country Link
JP (1) JP3117726B2 (id)
AR (1) AR006345A1 (id)
BG (1) BG64457B1 (id)
CO (1) CO4790151A1 (id)
HU (1) HU228026B1 (id)
ID (1) ID16781A (id)
IL (1) IL126185A (id)
MY (1) MY126358A (id)
OA (1) OA10880A (id)
PL (1) PL187919B1 (id)
TW (1) TW455491B (id)
WO (1) WO1997035587A1 (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2006036614A2 (en) * 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
EP1793806A2 (en) * 2004-09-30 2007-06-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
ATE163926T1 (de) * 1991-11-08 1998-03-15 Merck & Co Inc Hiv-protease-inhibitoren verwendbar in der aids- behandlung
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2170020C (en) * 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
WO1994015608A1 (en) * 1993-01-15 1994-07-21 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
JP3000564B2 (ja) * 1993-12-15 2000-01-17 メルク エンド カンパニー インコーポレーテッド Ｈｉｖプロテアーゼ阻害剤
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JPH11505257A (ja) * 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤

Also Published As

Publication number Publication date
PL328916A1 (en) 1999-03-01
MY126358A (en) 2006-09-29
OA10880A (en) 2001-10-11
JP3117726B2 (ja) 2000-12-18
WO1997035587A1 (en) 1997-10-02
HU228026B1 (en) 2012-08-28
HUP9901887A2 (hu) 1999-12-28
JP2000500504A (ja) 2000-01-18
BG64457B1 (bg) 2005-03-31
AR006345A1 (es) 1999-08-25
IL126185A0 (en) 1999-05-09
IL126185A (en) 2003-05-29
CO4790151A1 (es) 1999-05-31
HUP9901887A3 (en) 2000-02-28
PL187919B1 (pl) 2004-11-30
BG102838A (en) 1999-09-30
TW455491B (en) 2001-09-21

Similar Documents

Publication Publication Date Title
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
NO992339L (no) Farmasöytiske formuleringer
ID24654A (id) Formulasi farmasi omeprazola
ID18352A (id) Komposisi-komposisi farmasi
MA24473A1 (fr) Formulations
DE69530325D1 (de) Aerosol-arzneiformulierungen
FI20071025L (fi) Farmaseuttisia koostumuksia
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
FI991302L (fi) Parannetut farmaseuttiset koostumukset
ID16781A (id) Formulasi-formulasi farmasi
TR199501082A2 (tr) Farmasötik formülasyonlar.
ID29294A (id) Komposisi farmasi
ITMI941169A0 (it) Formulazioni farmaceutiche
PT941100E (pt) Composicoes farmaceuticas
EP0837863A4 (en) DISODIUM ALENDRONATE PREPARATIONS
ID25857A (id) Komposisi farmasi
EE03511B1 (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
FI951155L (fi) Farmaseuttinen valmiste
FI961364L (fi) Lääkeainekoostumus
ITMI962628A0 (it) Composizione farmaceutica
NO991430L (no) Insektfordrivende formuleringer
FI954050A7 (fi) Lääkekoostumuksia
ID23531A (id) Komposisi farmasi
SE9600141D0 (sv) Pharmaceutical formulation